The changes in corneal astigmatism after botulinum toxin-a injection in patients with blepharospasm.
To determine if the involuntary contractions of eyelids may have any effects on the development of corneal astigmatism, we performed this prospective study which includes 19 patients with either essential blepharospasm or hemifacial spasm. In hemifacial spasm, the degree of corneal astigmatism was evaluated between two eyes. Then the topographic changes were checked using vector analysis technique before and after passively opening the eyelids. They were also measured before and at 1 and 6 months after the injection of Botulinum toxin. Resultantly, 20 eyes had the with-the-rule (group1) and 9 eyes against-the-rule (group2) astigmatism. In hemifacial spasm, significantly more astigmatism was found at spastic eyes. The corneal topographic changes after passively opening the eyelids showed 10 eyes with the astigmatic shift to the with-the-rule, while the remaining 19 to the against the- rule. At 1 month after injection of Botulinum toxin, group 1 showed reduced average corneal astigmatism, whereas group 2 showed increased astigmatism. The astigmatic change vector showed significantly more against-the-rule. In the contrary, 6 months after treatment, corneal astigmatism again increased in group 1 and decreased in group 2. So they took on the appearance of pretreatment astigmatic status eventually. Conclusively eyelids may play an important role in corneal curvature.
Moon
Nam Ju
NJ
Department of Ophthalmology, College of Medicine, Chung-Ang University, Seoul, Korea.
Lee
Hyeon Il
HI
Kim
Jae Chan
JC
D000368:Aged; D001251:Astigmatism / Q000188:drug therapy* / Q000503:physiopathology; D001764:Blepharospasm / Q000188:drug therapy* / Q000503:physiopathology; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D003315:Cornea / Q000187:drug effects / Q000503:physiopathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005143:Eyelids / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A